1 – 10 of 913
- show: 10
- |
- sort: year (new to old)
- |
- Export
- 2025
- Immune checkpoint inhibitors in gynecologic cancer : getting to prime T(I)ME? (2025)
- Diagnostic utility of ERG immunostaining in dermatofibroma : be aware of ERG expression in cellular neurothekeoma (2025) JOURNAL OF CLINICAL PATHOLOGY.
- Gastrointestinal Disease in Common Variable Immunodeficiency Disorder (CVID): Histological Patterns, Diagnostic Clues and Pitfalls for the Pathologist and Gastroenterologist (2025) Journal of Clinical Medicine. 14(2).
- 2024
- BIMAP : breast cancer intra-operative margin assessment using PET-CT (2024) ESMO OPEN. In ESMO Open 9(Supplement 4).
- VIMAP-trial : vulvar cancer intra-operative margin assessment using PET-CT (2024) ESGO 2024 Congress, Abstracts.
- Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022) (2024) CANCER IMMUNOLOGY IMMUNOTHERAPY. 74(1).
- Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial (2024) GYNECOLOGIC ONCOLOGY. 191. p.275-286
- Performance of MRI for detection of ≥pT1b disease in local staging of endometrial cancer (2024) CANCERS. 16(6).
- Fishing for personalized ovarian cancer therapy (2024)
- Method for co-registration of high-resolution specimen PET-CT with histopathology to improve insight into radiotracer distributions (2024) EJNMMI PHYSICS. 11(1).